16.4 C
New York
Tuesday, June 9, 2026

Tag: physicians

newssourceFORcompanyinformationcontent1marketreleases

U.S., Japan, and Taiwan Experts Gather at NUWA Forum — Over 200 Reproductive Specialists Explore the Future of Integrated Fertility Technology

Is Increased Use of PGT-A Always Better? Experts Call for Evidence-Based Use of Mosaic EmbryosChoosing the Right PGT-A Platform: NUWA Fertility and Global Experts Unite...

Neuronetics Reports Second Quarter 2025 Financial and Operating Results

Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

The Hidden Lung Infection Impacting Millions: World NTM Day Puts Spotlight on Awareness

With Annual NTM Case Rates Rising, Patients and Providers Are Urged to Recognize the Symptoms and Risks MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the...

Tickets on Sale Now, Karmanos Cancer Institute’s 3rd Annual Classic Cars for the Cure

DETROIT, Aug. 4, 2025 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute is gearing up for the third annual Classic Cars for the Cure on...

SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS

IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States.

James D. Thomas, MD, Becomes President of the American Board of Emergency Medicine

EAST LANSING, Mich., Aug. 1, 2025 /PRNewswire/ -- James D. Thomas, MD, is the newly elected President of the American Board of Emergency Medicine...

Government of Canada expanding health care to more Indigenous communities

SASKATOON, SK, Aug. 1, 2025 /CNW/ - The Government of Canada is committed to helping small and medium-sized businesses transform their innovative ideas into real-world...

Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist & Hematologist Nikhita Kathuria-Prakash, MD To Columbia County

FORT MYERS, Fla., Aug. 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that medical oncologist and hematologist Nikhita...

Select Medical Holdings Corporation Announces Results For Its Second Quarter Ended June 30, 2025 and Cash Dividend

MECHANICSBURG, Pa., July 31, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its...

El Camino Health Recognized Among Nation’s Best Hospitals by U.S. News & World Report for 2025-2026

Mountain View Top Ranked Community Hospital and #2 Overall in San Jose Metro Area MOUNTAIN VIEW, Calif., July 31, 2025 /PRNewswire/ -- El Camino Health...

Expert insights about the impact of plastics on health, combating medical misinformation, and implementing AI in the clinic draw nearly 16,500 attendees to ADLM...

CHICAGO, July 31, 2025 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), welcomed thousands of laboratory experts to ADLM 2025...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPhysicians

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers